Cancer health disparities may exist based on the facility type. We aimed to determine the association between the academic status of centers and outcomes of patients with acute myeloid leukemia (AML). Using the National Cancer Data Base, we compared 1-month mortality and longterm overall survival (OS) of 60 738 patients with AML, who received first course treatment between 2003 and 2011 at academic or nonacademic centers (community cancer program, comprehensive community cancer program, and others). Multivariate analysis was done using logistic regression for one-month mortality and Cox regression with backward elimination approach for OS. Patients treated at academic centers differed from those at nonacademic centers in that they were younger with a median age of 62 versus 70 years (P < .0001), more often an ethnic minority (P < .0001), had lower education level (P 5 .005), lower co-morbidity score (P < .0001), a different income (P < .0001), and insurance profile (P < .0001), and more often received chemotherapy (P < .0001) and transplant (P < .0001). Receipt of care at nonacademic centers was associated with worse 1-month mortality (29% vs. 16%, P < .0001) and 5-year OS (15% vs. 25%; P < .0001). After adjusting for prognostic covariates, the 1-month mortality (odds ratio, 1.52; 95% confidence interval, CI 1.46-1.59; P < .0001) and OS were significantly worse in nonacademic centers, compared to academic centers. Our large database study suggests that the receipt of initial therapy at academic centers is associated with lower 1-month mortality and higher long-term OS. Investigation of the underlying reasons may allow reducing this disparity.
Cancer health disparities may exist based on the facility type. We aimed to determine the association between the academic status of centers and outcomes of patients with acute myeloid leukemia (AML). Using the National Cancer Data Base, we compared 1-month mortality and longterm overall survival (OS) of 60 738 patients with AML, who received first course treatment between 2003 and 2011 at academic or nonacademic centers (community cancer program, comprehensive community cancer program, and others). Multivariate analysis was done using logistic regression for one-month mortality and Cox regression with backward elimination approach for OS. Patients treated at academic centers differed from those at nonacademic centers in that they were younger with a median age of 62 versus 70 years (P < .0001), more often an ethnic minority (P < .0001), had lower education level (P 5 .005), lower co-morbidity score (P < .0001), a different income (P < .0001), and insurance profile (P < .0001), and more often received chemotherapy (P < .0001) and transplant (P < .0001). Receipt of care at nonacademic centers was associated with worse 1-month mortality (29% vs. 16%, P < .0001) and 5-year OS (15% vs. 25%; P < .0001). After adjusting for prognostic covariates, the 1-month mortality (odds ratio, 1.52; 95% confidence interval, CI 1.46-1.59; P < .0001) and OS were significantly worse in nonacademic centers, compared to academic centers. Our large database study suggests that the receipt of initial therapy at academic centers is associated with lower 1-month mortality and higher long-term OS. Investigation of the underlying reasons may allow reducing this disparity.
| I N T R O D U C T I O N
Prior studies have demonstrated that the quality of care and outcomes of cancer patients may differ by facility type. [1] [2] [3] [4] [5] [6] The discrepancy may become more evident in rare and more complex diseases or as the treatment complexity increases. 2, 3, 6 Overall survival (OS) of adolescents and young adults with acute promyelocytic leukemia may differ based on facility type. This was demonstrated in a large national database study of more than 8000 patients. 6 Recently, in a matched cohort study, we demonstrated that the inpatient mortality of patients with acute myeloid leukemia (AML) is significantly higher in low-volume centers, compared to high-volume centers. 2 We hypothesize that dedicated multidisciplinary leukemia teams in large academic centers are more likely to have expertise, adequate resources, standard operating policies and clinical trials to provide optimal management of complications and selection of optimal therapeutic strategy in complex cases of AML. In this large database study, we report on the impact of academic status of the facility on 1-month mortality and also OS of patients with AML. 
| Study endpoints and variables analyzed
The primary objective of this study was to determine whether the receipt of first course treatment at academic versus nonacademic centers is associated with any difference in 1-month mortality calculated from the time of diagnosis. As a secondary end point, we also deter- 
| Statistical analysis
Demographic-, disease-, and health system-related factors were compared according to facility type using Chi-square test for categorical data. 1-month mortality was calculated based on vital status at 1 month from diagnosis using the variables 'vital status,' and 'last contact or death, months from diagnosis.' Chi-square test was used to determine the relationship between 1-month mortality and categorical data.
All variables were used in a multiple logistic regression model to predict 1-month mortality, and backward selection was used to determine the final model. Due to the large number of subjects, the statistical level of significance was set to P < .001. Only covariates with P .001 were retained in the final model. Two way interactions with facility type were tested. Odds ratio (OR) and 95% confidence interval (CI) were presented for each of the variables in the final model.
OS was calculated in months based on vital status at last contact or time of death from diagnosis. Kaplan-Meier curves were presented for facility types and compared using the log rank test. The P values from the log rank test of the survival analysis for each variable were presented. All variables were included in a multivariate Cox proportional hazard model, and the model was reduced using backward elimination where 0.001 was the criteria for a term to remain in the model.
Two way interactions with facility type were tested. The hazard ratio, 95% CI, and P values are presented for each term in the final model.
The proportional hazards assumption was checked by correlating the residuals from the model with the time variable. All correlation coefficients were less than 0.015. Random intercept models for 1-month mortality and OS were fit accounting for the clustering of facilities.
These results were similar to the results reported in this paper, and hence not presented. Statistical analysis was done using PC SAS version 9.4.
| R E S U L T S
A total of 60 738 AML patients were studied, of which 29 939 (49%)
patients received treatment at academic centers. Patients treated at nonacademic centers mainly included those managed in comprehensive community cancer program (44%, n 5 27 007); a smaller number of patients received care at community cancer program (6%, n 5 3759), and other facilities (n 5 33). Academic centers, compared to nonacademic centers, were more likely to treat younger patients (median age 62 vs. 70 years), African Americans (10% vs. 7%), and those with comorbidity score of 0 (74% vs. 69%) ( Table 1) . Patients, who received treatment at academic centers versus nonacademic centers, were more to receive care at academic centers. Patients treated at academic centers were more likely to receive chemotherapy (85% vs. 65%, P < .0001) and undergo upfront HCT (12% vs. 3%, P < 0.0001). Information Table 2 and Supporting Information Table 3 ). Race (P < .0001), educational status (P 5 .0002), income (P < .0001), facility location (P 5 .01), insurance status (P < .0001), and distance traveled (P < .0001) were other factors associated with 1-month mortality. 1-month mortality was different when centers were divided into academic, comprehensive community cancer program, community cancer program and other facilities. 1-month mortality varied based on histology with a risk of 19% for acute promyelocytic leukemia, 13% for core binding factor AML, and 23% for nongood risk AML.
In a multivariate analysis, 1-month mortality was significantly worse in nonacademic centers as compared to academic centers (OR 1.52; 95% CI 1.46-1.59; P < .0001) ( Table 2 ). Younger age (P < .0001), subtypes of AML other than acute promyelocytic leukemia (P < .0001), absence of comorbidities (P < .0001), higher income status (P < .0001), availability of private insurance/managed care (P < .0001) and longer distance traveled (P < .0001) were other factors associated with lower risk of 1-month mortality. None of the two way interactions with facility type were statistically significant. Figures 2 and 3 ). Two interactions, facility type by age and facility type by histology, were statistically significant in the Cox regression model. The OS was significantly worse in nonacademic centers as compared to academic centers for each level of age and histology after adjusting for sex, race, Charlson co-morbidity score, receipt of chemotherapy, HCT, facility location, insurance, and income status (Table 3) . Although the OS for each histology was higher for patients treated in academic centers, the magnitude of difference was the greatest for patients with acute promyelocytic leukemia (HR 1.36; 95% CI, 1.24-1.49, P < .0001), as compared to core binding factor AML (HR 1.26; 95% CI, 1.11-1.43, P 5 .0003) and nongood risk AML (HR 1.03; 95% CI, 1.01-1.05, P 5 .005).
D I S C U S S I O N
Using the large National Cancer Data Base, we found that there were differences in the characteristics of patients with AML treated at academic versus nonacademic centers. Specifically, patients treated at academic centers tended to be younger, with fewer comorbidities, but also were more often of ethnic minorities, with less education and traveled farther to receive their care. Patients at academic centers more often were treated with chemotherapy and HCT. In multivariate analysis, many of these factors influenced 1-month mortality, with less mortality associated with younger age, fewer comorbidities, higher income status, private insurance/managed care status, and non-acute promyelocytic leukemia subtype.
After adjusting for these factors, 1-month mortality was significantly worse in nonacademic centers compared to academic centers. Similarly, in multivariate analysis, younger age, female gender, nonAfrican American ethnic group, fewer co-morbidities, higher income status private insurance/managed care status, and acute promyelocytic leukemia subtype and receipt of chemotherapy and HCT were all associated with improved OS, and after adjusting for these, survival was superior at academic centers.
The differences we found in the AML patient populations seen at academic versus nonacademic centers have not been previously reported, and were somewhat unexpected. The younger age and fewer co-morbidities among patients seen at academic centers might have been predicted, but the increased racial diversity, lower education levels were less anticipated, and not readily explained by urban versus rural location which were largely similar between groups. It should be acknowledged that these differences in characteristics, while highly statistically significant given the large numbers of patients involved,
were not dramatic from a quantitative standpoint.
The factors we identified in multivariate analysis to be associated Patients treated at academic centers more often received chemotherapy and this may account in part for the improved OS. However, other factors may be important. In other complex medical disorders, expertise of the providers, improved compliance with standard guidelines, and availability of greater resources are felt to contribute to improved outcomes in larger volume centers. 12, 13 In the context of AML, academic centers may have dedicated multidisciplinary leukemia teams able to timely diagnose and fully characterize AML, select optimal initial and subsequent therapy, provide protocol delivery of care 14 including leukemia therapy and supportive care, and quickly recognize and better manage potential complications. 2, 6 Although not consistently demonstrated, provision of clinical trials in academic centers for 4 In allogeneic HCT, larger physician caseload indicative of larger procedural volume, physicians answering after-hour calls and involvement of senior trainees such as fellows were associated with lower 100-day mortality. This demonstrates that greater involvement of properly trained experts influences the outcomes of complex treatment. 3 Although not determined by this study, similar factors may determine the differences in outcomes of AML based on facility type.
The study presented here has a number of limitations. The NCDB is a selected database and only a subset of AML patients are reported.
AML may be underreported in cancer registries. 17 NCDB gathers data only from Commission on Cancer-approved facilities, which have important differences from nonapproved facilities in terms of size, location and availability of cancer-related services available. 18 Many important relevant patient and disease characteristics were not available, including functional status and molecular characteristics of the disease.
Thus, there could be important unrecognized differences among patient populations that could have influenced the findings. And finally, even if we do accept that there is a difference in 1-month and overall mortality between academic and nonacademic centers, the reasons for 
